Table 4.

Treatment effects in patients with GC/GEJC/EAC, with negative/unknown HER2, on first-line treatment

Observations	Total n = 682	France n = 168	Germany n = 146	UK n = 145	US n = 99	Japan n = 36	China n = 88
Time since start of first-line treatment, days	629	158	139	123	88	35	86
Mean (SD)	90 (163)	80 (93)	78 (86)	62 (43)	125 (370)	177 (193)	95 (69)
Median (IQR)	62 (30–103)	51 (26–99)	62 (30–987)	49 (30–85)	58 (30–103)	166 (30–250)	81 (50–122)
Response to current therapy, n (%)	469	86	112	84	73	30	84
Stable disease	166 (35.4)	32 (37.2)	41 (36.6)	25 (29.8)	25 (34.3)	16 (53.3)	27 (32.1)
Partial response	273 (58.2)	49 (57.0)	67 (59.8)	59 (70.2)	38 (52.1)	10 (33.3)	50 (59.5)
Complete response	8 (1.7)	2 (2.3)	0 (0.0)	0 (0.0)	4 (5.5)	0 (0.0)	2 (2.4)
Disease progression	22 (4.7)	3 (3.5)	4 (3.6)	0 (0.0)	6 (8.2)	4 (13.3)	5 (6.0)
Nonpharmacological treatments, n (%)	682	168	146	145	99	36	88
Surgery	162 (23.8)	19 (11.3)	65 (44.5)	11 (7.6)	17 (17.2)	7 (19.4)	43 (48.9)
Radiotherapy	103 (15.1)	17 (10.1)	35 (24.0)	10 (6.9)	22 (22.2)	1 (2.8)	18 (20.5)
Stent	72 (10.6)	16 (9.5)	12 (8.2)	30 (20.7)	10 (10.1)	3 (8.3)	1 (1.1)
Laser therapy	5 (0.7)	0 (0.0)	4 (2.7)	0 (0.0)	1 (1.0)	0 (0.0)	0 (0.0)
None	5 (0.7)	0 (0.0)	4 (2.7)	0 (0.0)	1 (1.0)	0 (0.0)	0 (0.0)
Bothered by side effects, n (%)	676	166	144	145	98	35	88
Not at all	81 (12.0)	8 (4.8)	10 (6.9)	21 (14.5)	22 (22.5)	2 (5.7)	18 (20.5)
A little bit	212 (31.4)	62 (37.4)	42 (29.2)	48 (33.1)	27 (27.6)	15 (42.9)	18 (20.5)
Somewhat	247 (36.5)	51 (30.7)	67 (46.5)	55 (37.9)	25 (25.5)	14 (40.0)	35 (39.8)
Quite a bit	110 (16.3)	42 (25.3)	19 (13.2)	14 (9.7)	19 (19.4)	3 (8.6)	13 (14.8)
Very much	26 (3.9)	3 (1.8)	6 (4.2)	7 (4.8)	5 (5.1)	1 (2.9)	4 (4.6)

EAC Esophageal adenocarcinoma, GC Gastric cancer, GEJC Gastroesophageal junction cancer, HER2 Human epidermal growth factor receptor 2, IQR Interquartile range, SD Standard deviation, UK United Kingdom, US United States